|
Oct 9
|
FDA Grants Orphan Drug Designation to Can-Fite’s Namodenoson for Pancreatic Cancer
|
|
Oct 7
|
Join Can-Fite’s Exclusive Live Investor Webinar and Q&A Session on October 29
|
|
Jul 29
|
Can-Fite Provides Namodenoson Patent Update
|
|
Jun 24
|
Can-Fite: Breakthrough Findings Demonstrate Namodenoson Anti-cancer and Protective Effect Mechanism in the Liver
|
|
May 23
|
Join Can-Fite’s Exclusive Live Investor Webinar and Q&A Session on June 6
|
|
Dec 20
|
The Anti-Obesity Effect of Can-Fite’s Namodenoson: Molecular Mechanism of Action in Pre-clinical and Human Studies
|
|
Dec 4
|
Can-Fite’s Namodenoson for the Treatment of Pancreatic Cancer Patients: Progress in Clinical Development
|
|
Nov 30
|
Can-Fite Reports Third Quarter 2023 Financial Results and Clinical Update
|
|
Oct 27
|
Best Momentum Stocks to Buy for October 27th
|
|
Oct 27
|
New Strong Buy Stocks for October 27th
|
|
Oct 26
|
Can-Fite to Harness Artificial Intelligence to Develop Novel Anti-Cancer Drugs
|
|
Aug 24
|
Can-Fite Enters Rare Genetic Disease Field Based on impactful findings of a Fondazione Telethon and Naples University Researcher showing Piclidenoson is efficacious in Treating Lowe Syndrome
|
|
Jul 17
|
Can-Fite: Granted Breakthrough Abstract Award for Namodenoson in Treatment of Advanced Liver Cancer by ASCO Conquer Cancer Foundation
|